Blue Owl Capital's stock has dropped about 61.5% from its peak, making it heavily undervalued. The company is well-positioned to benefit from the growing AI trend, which the market has not fully recognized. Its digital infrastructure already contributes 6% to assets under management, and management expects significant growth from this area. The stock is expected to deliver high double-digit returns as real asset initiatives boost revenue and profits, though its valuation may not reach peers like Ares or Brookfield Asset Management.
Blue Owl Capital's recent performance is provided here as context for readers. For those following the US financial sector, 36 of 81 priced stocks rose and 44 fell on Pluang today. Notable movers include Bit Digital Inc (BTBT) at USD 1.73 with a 13.07% increase and Coinbase Global, Inc. (COIN) at USD 194.25 with an 11.66% rise, as of Sep 19, 2026 18:51 WIB.
Cryptocurrency markets display varied price changes, with Bitcoin trading above $81,000, up 4.2%. Ethereum and Binance Coin also rise by 5.68% and 3.18% respectively. Several altcoins such as AVAX and ENA see significant gains, with AVAX up 15.83% an...
Palantir Technologies showed impressive revenue growth of over 90% year-over-year in Q2 2026, driven by strong demand in enterprise AI. A $5,000 investment in Palantir today could be worth about $6,181 in five years under the base case scenario, refl...
Three US-listed junior uranium miners—Uranium Energy, Denison Mines, and NexGen Energy—are positioned to benefit from the growing demand for nuclear fuel driven by new reactor builds and US policy support. Uranium Energy is the only one currently pro...
The Goldman Sachs S&P 500 Premium Income ETF (GPIX) remains attractive despite recent Federal Reserve rate hikes, thanks to its dynamic call overwrite strategy that adapts monthly. GPIX captures 85.7% of the S&P 500's total return while delivering an...
Amgen and Merck both pay quarterly dividends and raise them annually, but Amgen offers a higher yield (2.6% vs. 2.29%) and has consistently raised dividends by about 6% annually. While Merck relies heavily on its Keytruda franchise, facing a looming ...
